Welcome to our dedicated page for Abeona Therapeut news (Ticker: ABEO), a resource for investors and traders seeking the latest updates and insights on Abeona Therapeut stock.
Abeona Therapeutics Inc (NASDAQ: ABEO) is a clinical-stage biopharmaceutical leader advancing gene therapies for rare genetic diseases. This dedicated news hub provides investors and researchers with essential updates on ABEO’s therapeutic developments, regulatory milestones, and scientific partnerships.
Discover timely press releases detailing progress in AAV-based therapies, CRISPR/Cas9 research, and pivotal clinical trials for conditions like epidermolysis bullosa. Our curated collection includes FDA correspondence updates, manufacturing quality certifications, and strategic collaboration announcements – all critical for evaluating the company’s trajectory.
Key content categories feature BLA submission statuses, Phase 3 trial results, and technology licensing agreements. Bookmark this page for streamlined access to verified updates about ABEO’s pipeline candidates and operational developments, presented with clarity for both professional analysts and engaged stakeholders.
Abeona Therapeutics has successfully completed a Type B meeting with the FDA regarding the co-primary endpoints for the Phase 3 VIITAL™ study of EB-101, a treatment for recessive dystrophic epidermolysis bullosa (RDEB). The study aims to enroll 10-15 patients with over 35 chronic wound sites. The co-primary endpoints include a 50% healing threshold and pain reduction upon wound dressing changes, evaluated at Week 24. Previous trials showed durable wound healing effects with no pain at treated sites lasting 2-5 years. The company is preparing for patient enrollment in 2021.
Abeona Therapeutics (Nasdaq: ABEO) announced interim results from its ABO-102 and ABO-101 Phase 1/2 studies for MPS IIIA and MPS IIIB, respectively. These results will be presented at the 17th Annual WORLD Symposium on February 12, 2021. The Transpher A study focuses on ABO-102's ability to preserve neurocognitive development in young patients, while Transpher B will provide insights into ABO-101's effects. Both therapies target rare lysosomal storage diseases with no approved treatments. Abeona holds multiple designations from regulatory agencies for these therapies.
Abeona Therapeutics Inc. (Nasdaq: ABEO) reported its third quarter 2020 financial results, highlighting a net loss of $7.2 million, down from a $17.4 million loss in Q3 2019. The company received $7 million from licensing agreements with Taysha Gene Therapies for ABO-202 and $3 million for Rett syndrome gene therapy. R&D expenses decreased to $8 million due to COVID-19 impacts. Abeona continues clinical trials for RDEB and MPS IIIA/B, aiming for regulatory submissions in 2021. Cash reserves were $103.9 million as of September 30, 2020.
Abeona Therapeutics Inc. (Nasdaq: ABEO) announced the promotion of Michael Amoroso to Chief Operating Officer, effective November 1, 2020. This newly created role expands his oversight to include all company operations, encompassing research, clinical development, and business strategies. Amoroso brings over 20 years of experience in biotechnology, previously holding senior positions at Kite and Celgene. The company's focus remains on advancing significant clinical programs for rare diseases, including pivotal studies for recessive dystrophic epidermolysis bullosa and Sanfilippo syndrome.
Abeona Therapeutics Inc. (NASDAQ: ABEO) has appointed Steven H. Rouhandeh as Chairman of its Board of Directors. The company has also established a Special Committee to guide executive leadership on operations and strategic direction, working closely with its team to advance gene and cell therapies. In addition, Abeona has engaged Jefferies LLC as a financial advisor to explore strategic options to enhance stakeholder value, with no specific timeline for this review. The company is known for its innovative clinical programs focusing on serious diseases and aims to maximize its mission.
Abeona Therapeutics Inc. (Nasdaq: ABEO) announced significant changes in its leadership and Board of Directors on September 28, 2020. João Siffert, M.D. resigned as CEO and other key positions on September 23, followed by the resignation of five Board members on September 27. The company is now exploring various strategic options, including potential asset sales, though no specific timelines or outcomes are guaranteed. Abeona is focused on developing gene and cell therapies for serious diseases, with several clinical programs underway, including EB-101, ABO-101, and ABO-102.
Abeona Therapeutics Inc. (Nasdaq: ABEO) reported significant changes in its leadership as CEO João Siffert, M.D. resigned, along with several board members on September 23 and 27, 2020. The company is now evaluating strategic options, including potential asset sales, although no specific timeline or outcomes are guaranteed. Abeona specializes in gene and cell therapies for serious diseases, with ongoing clinical programs in Phase 1/2 and Phase 3 development. The company highlights its AAV-based gene therapies and GMP manufacturing capabilities, essential for its clinical trials.
Abeona Therapeutics Inc. (Nasdaq: ABEO) announced its participation in key investor conferences in September 2020. CEO João Siffert will engage in virtual one-on-one meetings at Citi’s 15th Annual BioPharma Virtual Conference on September 9. Additionally, he will present at the Wells Fargo Virtual Healthcare Conference on September 10 at 10:00 a.m. ET, with a live webcast available on Abeona’s website. Abeona focuses on gene and cell therapies for serious diseases, including programs for recessive dystrophic epidermolysis bullosa and Sanfilippo syndrome.
Abeona Therapeutics Inc. (Nasdaq: ABEO) and Taysha Gene Therapies have entered into agreements for the licensing and purchase of inventory related to ABO-202, a gene therapy for CLN1 disease, also known as infantile Batten disease. Taysha will pay Abeona $7 million upfront, plus potential milestone payments up to $56 million and royalties on sales. The therapy aims to deliver a functional copy of the PPT1 gene, addressing a critical unmet medical need. Abeona will focus on advancing its other clinical programs post-agreement.
Abeona Therapeutics (Nasdaq: ABEO) reported significant clinical advancements and financial results for Q2 2020. The firm resumed patient enrollment in pivotal studies for RDEB and MPS IIIA, with new patients treated in both programs. Abeona aims for a 2023 EU marketing application for ABO-102 and anticipates commercial launches of EB-101 in late-2022. Financially, the company held $107.9 million in cash, with a net loss of $13 million for Q2. Leadership strengthened with a new Chief Commercial Officer and board members, enhancing strategic direction.
FAQ
What is the current stock price of Abeona Therapeut (ABEO)?
What is the market cap of Abeona Therapeut (ABEO)?
